BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, April 14, 2026
Home » Authors » Haky Moon

Articles by Haky Moon

New manufacturing deal a win-win for Sun Pharma and Samsung Biologics

July 7, 2017
By Haky Moon
HONG KONG – Facing increased U.S. regulatory scrutiny, India's largest drugmaker, Sun Pharmaceutical Industries Ltd., is outsourcing some of its manufacturing in a deal that provides South Korea's Samsung Biologics Co. Ltd., the biologics manufacturing arm of the Samsung conglomerate, an opportunity to expand its market share.
Read More

U.S. stent makers view India price caps with suspicion

July 6, 2017
By Haky Moon

India's medical device parks projected to reduce product import dependency

June 27, 2017
By Haky Moon

Genexine cleared to initiate second clinical trial of GX-188E

June 21, 2017
By Haky Moon
HONG KONG – The collaboration between Merck & Co. Inc. and South Korean company Genexine Inc. is just a few steps away from tackling human papillomavirus (HPV)-associated cancers, with Genexine receiving the go-ahead from the South Korean Ministry of Food and Drug Safety (MFDS) for a phase Ib/II trial testing a combination vaccine.
Read More

Korea's Orum Therapeutics raises $8M in series A financing

June 21, 2017
By Haky Moon
HONG KONG – South Korean startup Orum Therapeutics Inc. has a shot at effectively blocking RAS gene function with an innovative technology co-developed with Ajou University in South Korea and last week raised $8 million in a series A round to advance work in oncology indications.
Read More

Genexine cleared to initiate second clinical trial of GX-188E

June 21, 2017
By Haky Moon
HONG KONG – The collaboration between Merck & Co. Inc. and South Korean company Genexine Inc. is just a few steps away from tackling human papillomavirus (HPV)-associated cancers, with Genexine receiving the go-ahead from the South Korean Ministry of Food and Drug Safety (MFDS) for a phase Ib/II trial testing a combination vaccine.
Read More

Price controls have India's med-tech industry bracing for negative implications

June 19, 2017
By David Ho and Haky Moon

Korea's Orum Therapeutics raises $8M in series A financing

June 19, 2017
By Haky Moon
HONG KONG – South Korean startup Orum Therapeutics Inc. has a shot at effectively blocking RAS gene function with an innovative technology co-developed with Ajou University in South Korea and last week raised $8 million in a series A round to advance work in oncology indications.
Read More

AI health care boom coming to China as new solutions are desparately needed

June 12, 2017
By Haky Moon

South Korea imports less med-tech products while local production grows

June 8, 2017
By Haky Moon
Previous 1 2 3 4 5 6 7 8 9 … 17 18 Next

Popular Stories

  • Today's news in brief

    BioWorld
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • MSD discloses new HCN1/2 blockers

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
  • Cancer cell in the cross-hairs

    Selective CBL-B inhibitor with improved safety profile disclosed

    BioWorld Science
    CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing